Cytotoxicity evaluation of CELNORM, a nutritional health supplement, on MCF7 breast cancer cells

Abstract

Objective: To evaluate the in vitro cytotoxic potential of CELNORM, a nutritional health supplement, on MCF7 human adenocarcinoma breast cancer cells. Methods: Briefly, MCF7 cells were cultured for 24 hours in complete growth medium containing fetal bovine serum and antibiotics and exposed to various concentrations (500, 250, 125, 62.5, 31.25, 15.625, 7.8125, 3.906 micrograms/mL) of CELNORM for a period of 24 hours. Cell viability/death was assessed qualitatively by microscopy and quantitatively by MTT assay. Findings: CELNORM exhibited significant cytotoxic effect on MCF-7 cells in a dose dependent manner. Under microscopy, there was an evident, dosedependent increase in the number of apoptotic cells. Cell viability exhibited in terms of percentage viability, fell below 70% from 7.9 µg/mL, which is indicative of cytotoxic response from this dose. The IC 50 value was determined to be 43.51 µg/mL. Applications: With such an effective combination of natural ingredients, the results are promising. Therefore, we conclude that CELNORM can be a useful option in the supplemental therapy for breast cancer treatment in the panel of Complementary and Alternative Medicine (CAM).

Anti-cancer Properties of Dietary Supplement CELNORM against Colon and Lung Cancer: An in vitro preliminary study

“…Curcumin, when combined with other natural substances, significantly increased clonogenic inhibition and induced cell apoptosis. One previous study that showed the efficacy of CELNORM on breast cancer has detailed its action against halting the proliferation of breast cancer cells when tested in MCF7 cell lines (Sathya et al, 2020). In terms of morphological features and cell proliferation inhibition, this combination of therapies generated a consistent response in both colon and lung cancer cell lines.…”

“…At first, stock of CELNORM and its constituent have been made at a concentration of 1mg/ml in DMEM containing 300 µl of DMSO. Then two groups (A and B) of extract supplemented with DMEM were prepared at different concentrations individually with all four extracts and CELNORM according to the previously published work (Sathya et al, 2020). Two cell lines (HCT116 and A549 cells) were used separately to study the effect of CELNORM and its components in the two treatment groups individually.…”

“…Our previous study has shown combinational treatments of multiple extracts are beneficial when used as a treatment for breast cancer cell lines (Sathya et al, 2020), apart from this, the direct prevention or elimination of harmful factors (such as cancer cells or pathogens), as well as the synergistic stimulation of defences or healing processes of the human body, is also the focus of combinational therapies. Thus, cancer can be lessened by increasing the consumption of natural compounds that might alter important molecular signalling cascades, ultimately inhibiting cancer cells' proliferation and inducing apoptosis (Surh, 2003).…”

Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends

“…Treating A549 cells with cucurbitacins for ~21 days showed positive results for inhibiting metastasis by regulating the levels of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D11 [64]. Similarly, other cucurbitacins were observed to inhibit angiogenesis in MDA-MB-231 and MCF-7 cancer cells by inhibiting the JAK/STAT pathways [65].…”